PDS Biotechnology Corporation (NASDAQ:PDSB) Receives Patent Covering The Versamune® Tech Platform

0
PDS Biotechnology Corporation (NASDAQ:PDSB) has announced that it has received a patent for its proprietary Versamune® T-cell activating technology by the USPTO. The company...

The US FDA Approves The Expanded Manufacturing Process Of ADMA Biologics...

0
ADMA Biologics Inc (NASDAQ:ADMA) announced the US FDA approval for its expanded manufacturing process. It allows the company to manufacture IVIG (Intravenous Immune Globulin)...

Galera Therapeutics Inc (NASDAQ:GRTX) Reports Updated Results Of Phase 1/ 2...

0
Galera Therapeutics Inc (NASDAQ:GRTX) issued an update on multi-centre, double-blind, randomized and placebo-controlled Phase 1/2 clinical study results of GC4419 in SBRT treated patients...

Popular News

MAKE IT MODERN

LATEST REVIEWS

Incyte (NASDAQ:INCY) Releases Phase 3 Jakafi® In Combination with SOC Study...

0
Incyte  (NASDAQ:INCY) has released initial data from the phase 3 RUXCOVID study which showed that ruxolitinib (Jakafi®) combination with standard of care...

MAKE IT MODERN

PERFORMANCE TRAINING

Cue Biopharma Inc (NASDAQ:CUE) Advances CUE-101 Dose Escalation Phase 1 Monotherapy Clinical Trial

0
Cue Biopharma Inc (NASDAQ:CUE) received encouraging results in the cohort 5 and cohort 4 dosing and got clearance from the SRC (Safety Review Committee)....

B2Digital Inc. (OTCMKTS:BTDG) Drops Bomb in Front of Huge PPV Events Series

0
The big story in the OTC marketplace right now is the rise of B2Digital Inc (OTCMKTS:BTDG). The developing narrative around this stock is rich...

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Secures FDA Green Light For Upneeq

0
Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) recently announced that Upneeq, its innovative treatment for ptosis or acquired blepharoptosis, received regulatory approval from the FDA. Acquired blepharoptosis is...

US FDA Gives Nod For Kitov Pharma Lt (NASDAQ:KTOV) To Conduct Phase 1/2 Clinical...

0
US FDA has accepted the IND Investigational New Drug application and permitted Kitov Pharma Lt (NASDAQ:KTOV) to launch phase 1/2 clinical study of NT219...

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5...

0
While no one is immune to contracting the global coronavirus, Karyopharm Therapeutics Inc (NASDAQ:KPTI) says it has been putting together every effort to bring...

MAKE IT MODERN

POPULAR

[/tdc_zone]

.td-post-views{ display: none !important; }